


## PHARMACEUTICAL 2021

## Corvus Pharmaceuticals Inc. Rank 58 of 402







## PHARMACEUTICAL 2021



## Corvus Pharmaceuticals Inc. Rank 58 of 402

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 191% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	45,336
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,149
Liabilities, Non-Current	1,232
Other Assets	39,287
Other Compr. Net Income	-25
Other Expenses	0
Other Liabilities	0
Other Net Income	37,765
Other Revenues	0
Property and Equipment	906
Research and Development	31,830
Selling, General and Administrative Expense	11,930

Output Variable	Value in 1000 USD
Assets	85,529
Liabilities	13,381
Expenses	43,760
Revenues	0
Stockholders Equity	72,148
Net Income	-5,995
Comprehensive Net Income	-6,008
Economic Capital Ratio	239%

